Evidence map›Paper›PMID 35835296›Full record

ArticleTransplant immunology2022

SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies.

Veerle P W M Wijtvliet, Sonja Verheyden, Barbara Depreter, Christine Heylen, Elke Coeman, Steven Abrams, Benedicte Y De Winter, Annick Massart, Rachel Hellemans, Lissa Pipeleers and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Veerle P W M WijtvlietLaboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Edegem, Belgium; Department of Nephrology and Hypertension, Antwerp University Hospital, Edegem, Belgium. Electronic address: veerle.wijtvliet@uantwerpen.be.
Sonja VerheydenDepartment of Hematology, HLA and Molecular Hematology Laboratory, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Barbara DepreterDepartment of Hematology, HLA and Molecular Hematology Laboratory, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Christine HeylenImmucor Inc., Norcross, GA, United States.
Elke CoemanImmucor Inc., Norcross, GA, United States.
Steven AbramsDepartment of Family Medicine and Population Health, Global Health Institute, University of Antwerp, Antwerp, Belgium; I-BioStat, Data Science Institute, Hasselt University, Diepenbeek, Belgium.
Benedicte Y De WinterLaboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Edegem, Belgium.
Annick MassartLaboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Edegem, Belgium; Department of Nephrology and Hypertension, Antwerp University Hospital, Edegem, Belgium.
Rachel HellemansLaboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Edegem, Belgium; Department of Nephrology and Hypertension, Antwerp University Hospital, Edegem, Belgium.
Lissa PipeleersDepartment of Nephrology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Frans H J ClaasLaboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Edegem, Belgium; Department of Immunology, Leiden University Medical Center, Leiden, Netherlands.
Kevin K AriënDepartment of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Karl Martin WissingDepartment of Nephrology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Daniel AbramowiczLaboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Edegem, Belgium; Department of Nephrology and Hypertension, Antwerp University Hospital, Edegem, Belgium.
Kristien J LedeganckLaboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Edegem, Belgium.
University of Antwerp · BEUniversitair Ziekenhuis Brussel · BEAntwerp University Hospital · BEImmucor (United States) · USHasselt University · BEVrije Universiteit Brussel · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2 vaccination is strongly recommended in kidney transplant recipients (KTR) and dialysis patients. Whether these vaccinations may trigger alloantibodies, is still debated.

methodsIn the current study we evaluated the effect of SARS-CoV-2 mRNA vaccines on anti-Human Leukocyte Antigen (HLA) and 60 anti-non-HLA antibody profiles in clinically stable KTR and dialysis patients. In total, we included 28 KTR, 30 patients on haemodialysis, 25 patients on peritoneal dialysis and 31 controls with a positive seroresponse 16-21 days after the first dose of either the SARS-CoV-2 mRNA BNT162b2 or mRNA-1273 vaccine. Both anti-HLA and anti-non-HLA antibodies were determined prior to vaccination and 21 to 35 days after the second vaccine dose.

resultsOverall, the proportion of patients with detectable anti-HLA antibodies was similar before and after vaccination (class I 14% vs. 16%, p = 0.48; class II 25% before and after vaccination). After vaccination, there was no pattern in 1) additionally detected anti-HLA antibodies, or 2) the levels of pre-existing ones. Additional anti-non-HLA antibodies were detected in 30% of the patients, ranging from 1 to 5 new anti-non-HLA antibodies per patient. However, the clinical significance of anti-non-HLA antibodies is still a matter of debate. To date, only a significant association has been found for anti-non-HLA ARHGDIB antibodies and long-term kidney graft loss. No additionally developed anti-ARHGDIB antibodies or elevated level of existing anti-ARHGDIB antibodies was observed.

conclusionThe current data indicate that SARS-CoV-2 mRNA vaccination does not induce anti-HLA or anti-non-HLA antibodies, corroborating the importance of vaccinating KTR and dialysis patients.

Indexed as

COVID-19SARS-CoV-22019-nCoV Vaccine mRNA-1273Antibodies, ViralBNT162 VaccineCOVID-19 VaccinesGraft RejectionHistocompatibility AntigensHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHumansRenal Dialysisrho Guanine Nucleotide Dissociation Inhibitor betaRNA, MessengerVaccination2019-nCoV Vaccine mRNA-1273Antibodies, ViralARHGDIB protein, humanBNT162 VaccineCOVID-19 VaccinesHistocompatibility AntigensHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA Antigensrho Guanine Nucleotide Dissociation Inhibitor betaRNA, MessengerAntibodiesHuman leukocyte antigen (HLA)Minor antigenSARS-CoV-2Vaccination

Identifiers

PMID35835296
PMCPMC9271456
OpenAlexW4285009709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.